Capian, France

Roselyne Dirson

This inventor holds 1 USPTO granted patent. Top assignee: Biovector Therapeutics, S.a.. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Roselyne Dirson: Innovator in Synthetic Particulate Vectors

Introduction

Roselyne Dirson is a prominent inventor based in Capian, France. She has made significant contributions to the field of biotechnology, particularly in the development of synthetic particulate vectors. Her innovative work has led to the creation of a patented process that holds promise for various applications in medicine and therapeutics.

Latest Patents

Roselyne Dirson holds a patent for "Synthetic particulate vectors and preparation process." This patent represents her pioneering efforts in creating novel delivery systems that can enhance the efficacy of therapeutic agents. The patent showcases her expertise and commitment to advancing scientific knowledge in her field. She has 1 patent to her name.

Career Highlights

Throughout her career, Roselyne has been associated with Biovector Therapeutics, S.A., a company dedicated to developing innovative biopharmaceuticals. Her role at the company has allowed her to work on cutting-edge projects that aim to improve patient outcomes through advanced therapeutic solutions.

Collaborations

Roselyne has collaborated with notable colleagues, including Daniel Samain and Pascal E Delrieu. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their work in the biotechnology sector.

Conclusion

Roselyne Dirson is a trailblazer in the field of synthetic particulate vectors, with a focus on innovative solutions for therapeutic applications. Her contributions to Biovector Therapeutics and her patented work exemplify her dedication to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…